New Barrett's Imaging Leads to Fewer Biopsies

White light endoscopic methods for Barrett's esophagus screening and surveillance could soon be overtaken by more accurate endoscopic techniques, the most promising of which appears to be narrow band imaging, based on new research.

Narrow band imaging (NBI) may offer the best combination of accuracy in detecting metaplasia, dysplasia, and cancer while reducing the number of biopsies necessary to detect changes in esophageal tissue.

White light endoscopy typically relies on random biopsy sampling using the four quadrant protocol to detect tissue changes, which endoscopists adhere to poorly, said Dr. Prateek Sharma, professor of medicine at the University of Kansas and the Veterans Affair Medical Center, Kansas City.

Other techniques, such as autofluorescence imaging and confocal endomicroscopy, potentially could serve complementary roles to white light endoscopy or NBI during screening and surveillance, said Dr. Sharma, who has evaluated NBI with his colleagues over the past 5 years.

“These technologies … have the ability in the future to dramatically change how we do biopsies in patients with Barrett's esophagus,” Dr. Sharma said in an interview.

The current standard of care for biopsying patients with Barrett's esophagus (BE)—the four-quadrant protocol—takes a random tissue biopsy every 90 degrees in every 2-cm length of esophagus that contains Barrett's metaplasia.

Dr. Sharma cited several reasons why the four-quadrant protocol is flawed. The random biopsying may miss dysplastic and cancerous segments in the Barrett's tissue because “if you take a biopsy in the 12 o'clock position, you are hoping that the dysplasia or early cancer is also in that position. It could be in the 1 o'clock or 2 o'clock position and you would just miss it.”

In addition, only about half of patients actually undergo the full biopsy protocol. A recent study of nearly 11,000 patients with BE who were undergoing surveillance biopsying in the Caris Diagnostics pathology database found that only 51% of patients underwent the full biopsy protocol as recommended by the American College of Gastroenterology Guidelines for BE Surveillance.

During esophageal endoscopy with NBI, white light is filtered to pass blue light (and some green light) to shine on esophageal tissue. Because hemoglobin in blood selectively absorbs blue light, clinicians can look for irregularities in the patterns of blood vessels or surface mucosa, which have been correlated with histologic findings of dysplasia or cancer in previous studies.

To determine if targeted biopsies with NBI could detect Barrett's metaplasia and dysplasia or cancer better than does high-definition white light endoscopy (HD-WLE) alone, Dr. Sharma and his colleagues at the VA Medical Center and two other centers (Amsterdam Medical Center and the Medical University of South Carolina, Charleston) conducted a study of 123 patients referred for BE screening or surveillance. They were randomized to an exam with HD-WLE, followed later by NBI, or first NBI and then HD-WLE. In each case, a separate investigator performed the second procedure 6-8 weeks after the first procedure without knowing the results of the first.

During HD-WLE, the investigators took biopsies with the four-quadrant technique in every 2-cm length of BE. The patients had an average age of nearly 60 years and were mostly men and white.

At the annual Digestive Diseases Week, Dr. Sharma reported that the rate of detection of intestinal metaplasia in the patients' biopsies—the study's primary end point—was 85% for each modality. The detection of patients with neoplasia (low- and high-grade dysplasia and/or cancer) lesions found in the patients also was not significantly different between NBI (71%) and HD-WLE (55%).

NBI detected more lesions overall with high-grade dysplasia or cancer than did HD-WLE (19 vs. 13). Lesions with any type of dysplasia (low- and high-grade dysplasia and cancer) also were found with NBI significantly more often than with HD-WLE (81 vs. 67).

Dr. Sharma receives grant and research support from Olympus America, manufacturer of the NBI device used in the study, and from Mauna Kea Technologies. The American Society for Gastrointestinal Endoscopy funded the study.

NBI shows irregular dysplastic Barrett's, confirmed by biopsy.

White light endoscopy shows nondysplastic Barrett's esophagus.

Source Images courtesy Dr. Prateek Sharma

White light endoscopic methods for Barrett's esophagus screening and surveillance could soon be overtaken by more accurate endoscopic techniques, the most promising of which appears to be narrow band imaging, based on new research.

Narrow band imaging (NBI) may offer the best combination of accuracy in detecting metaplasia, dysplasia, and cancer while reducing the number of biopsies necessary to detect changes in esophageal tissue.

White light endoscopy typically relies on random biopsy sampling using the four quadrant protocol to detect tissue changes, which endoscopists adhere to poorly, said Dr. Prateek Sharma, professor of medicine at the University of Kansas and the Veterans Affair Medical Center, Kansas City.

Other techniques, such as autofluorescence imaging and confocal endomicroscopy, potentially could serve complementary roles to white light endoscopy or NBI during screening and surveillance, said Dr. Sharma, who has evaluated NBI with his colleagues over the past 5 years.

“These technologies … have the ability in the future to dramatically change how we do biopsies in patients with Barrett's esophagus,” Dr. Sharma said in an interview.

The current standard of care for biopsying patients with Barrett's esophagus (BE)—the four-quadrant protocol—takes a random tissue biopsy every 90 degrees in every 2-cm length of esophagus that contains Barrett's metaplasia.

Dr. Sharma cited several reasons why the four-quadrant protocol is flawed. The random biopsying may miss dysplastic and cancerous segments in the Barrett's tissue because “if you take a biopsy in the 12 o'clock position, you are hoping that the dysplasia or early cancer is also in that position. It could be in the 1 o'clock or 2 o'clock position and you would just miss it.”

In addition, only about half of patients actually undergo the full biopsy protocol. A recent study of nearly 11,000 patients with BE who were undergoing surveillance biopsying in the Caris Diagnostics pathology database found that only 51% of patients underwent the full biopsy protocol as recommended by the American College of Gastroenterology Guidelines for BE Surveillance.

During esophageal endoscopy with NBI, white light is filtered to pass blue light (and some green light) to shine on esophageal tissue. Because hemoglobin in blood selectively absorbs blue light, clinicians can look for irregularities in the patterns of blood vessels or surface mucosa, which have been correlated with histologic findings of dysplasia or cancer in previous studies.

To determine if targeted biopsies with NBI could detect Barrett's metaplasia and dysplasia or cancer better than does high-definition white light endoscopy (HD-WLE) alone, Dr. Sharma and his colleagues at the VA Medical Center and two other centers (Amsterdam Medical Center and the Medical University of South Carolina, Charleston) conducted a study of 123 patients referred for BE screening or surveillance. They were randomized to an exam with HD-WLE, followed later by NBI, or first NBI and then HD-WLE. In each case, a separate investigator performed the second procedure 6-8 weeks after the first procedure without knowing the results of the first.

During HD-WLE, the investigators took biopsies with the four-quadrant technique in every 2-cm length of BE. The patients had an average age of nearly 60 years and were mostly men and white.

At the annual Digestive Diseases Week, Dr. Sharma reported that the rate of detection of intestinal metaplasia in the patients' biopsies—the study's primary end point—was 85% for each modality. The detection of patients with neoplasia (low- and high-grade dysplasia and/or cancer) lesions found in the patients also was not significantly different between NBI (71%) and HD-WLE (55%).

NBI detected more lesions overall with high-grade dysplasia or cancer than did HD-WLE (19 vs. 13). Lesions with any type of dysplasia (low- and high-grade dysplasia and cancer) also were found with NBI significantly more often than with HD-WLE (81 vs. 67).

Dr. Sharma receives grant and research support from Olympus America, manufacturer of the NBI device used in the study, and from Mauna Kea Technologies. The American Society for Gastrointestinal Endoscopy funded the study.

NBI shows irregular dysplastic Barrett's, confirmed by biopsy.

White light endoscopy shows nondysplastic Barrett's esophagus.

Source Images courtesy Dr. Prateek Sharma

White light endoscopic methods for Barrett's esophagus screening and surveillance could soon be overtaken by more accurate endoscopic techniques, the most promising of which appears to be narrow band imaging, based on new research.

Narrow band imaging (NBI) may offer the best combination of accuracy in detecting metaplasia, dysplasia, and cancer while reducing the number of biopsies necessary to detect changes in esophageal tissue.

White light endoscopy typically relies on random biopsy sampling using the four quadrant protocol to detect tissue changes, which endoscopists adhere to poorly, said Dr. Prateek Sharma, professor of medicine at the University of Kansas and the Veterans Affair Medical Center, Kansas City.

Other techniques, such as autofluorescence imaging and confocal endomicroscopy, potentially could serve complementary roles to white light endoscopy or NBI during screening and surveillance, said Dr. Sharma, who has evaluated NBI with his colleagues over the past 5 years.

“These technologies … have the ability in the future to dramatically change how we do biopsies in patients with Barrett's esophagus,” Dr. Sharma said in an interview.

The current standard of care for biopsying patients with Barrett's esophagus (BE)—the four-quadrant protocol—takes a random tissue biopsy every 90 degrees in every 2-cm length of esophagus that contains Barrett's metaplasia.

Dr. Sharma cited several reasons why the four-quadrant protocol is flawed. The random biopsying may miss dysplastic and cancerous segments in the Barrett's tissue because “if you take a biopsy in the 12 o'clock position, you are hoping that the dysplasia or early cancer is also in that position. It could be in the 1 o'clock or 2 o'clock position and you would just miss it.”

In addition, only about half of patients actually undergo the full biopsy protocol. A recent study of nearly 11,000 patients with BE who were undergoing surveillance biopsying in the Caris Diagnostics pathology database found that only 51% of patients underwent the full biopsy protocol as recommended by the American College of Gastroenterology Guidelines for BE Surveillance.

During esophageal endoscopy with NBI, white light is filtered to pass blue light (and some green light) to shine on esophageal tissue. Because hemoglobin in blood selectively absorbs blue light, clinicians can look for irregularities in the patterns of blood vessels or surface mucosa, which have been correlated with histologic findings of dysplasia or cancer in previous studies.

To determine if targeted biopsies with NBI could detect Barrett's metaplasia and dysplasia or cancer better than does high-definition white light endoscopy (HD-WLE) alone, Dr. Sharma and his colleagues at the VA Medical Center and two other centers (Amsterdam Medical Center and the Medical University of South Carolina, Charleston) conducted a study of 123 patients referred for BE screening or surveillance. They were randomized to an exam with HD-WLE, followed later by NBI, or first NBI and then HD-WLE. In each case, a separate investigator performed the second procedure 6-8 weeks after the first procedure without knowing the results of the first.

During HD-WLE, the investigators took biopsies with the four-quadrant technique in every 2-cm length of BE. The patients had an average age of nearly 60 years and were mostly men and white.

At the annual Digestive Diseases Week, Dr. Sharma reported that the rate of detection of intestinal metaplasia in the patients' biopsies—the study's primary end point—was 85% for each modality. The detection of patients with neoplasia (low- and high-grade dysplasia and/or cancer) lesions found in the patients also was not significantly different between NBI (71%) and HD-WLE (55%).

NBI detected more lesions overall with high-grade dysplasia or cancer than did HD-WLE (19 vs. 13). Lesions with any type of dysplasia (low- and high-grade dysplasia and cancer) also were found with NBI significantly more often than with HD-WLE (81 vs. 67).

Dr. Sharma receives grant and research support from Olympus America, manufacturer of the NBI device used in the study, and from Mauna Kea Technologies. The American Society for Gastrointestinal Endoscopy funded the study.

NBI shows irregular dysplastic Barrett's, confirmed by biopsy.

White light endoscopy shows nondysplastic Barrett's esophagus.

Source Images courtesy Dr. Prateek Sharma